Many studies have provided evidence for the role of hepatitis B and C viruses in the development of liver cancer. in Mashhad, Iran. ELISA method was used to determine the existence of anti-HCV antibody among HBV infected cases. Results: Of 34 HBsAg positive participants that included equal number of men and women (17 subjects of each gender) with the mean age of 49.9 years, none were positive for anti-HCV antibody. Conclusion: According to the current study, it could be concluded that the prevalence of HBV/HCV coinfection is low in Mashhad. However, since occult HBV infection may go unnoticed by conventional HBsAg testing, high sensitive molecular techniques are required to investigate the presence of dual infection.
Introduction
orldwide, a substantial proportion of liver diseases are caused by Hepatitis B virus (HBV) and Hepatitis C virus (HCV). According to The World Health Organization (WHO) figures, an estimated 170 million and 350 million individuals are chronic carriers of HCV and HBV, respectively (1) . Patients coinfected with hepatitis B virus (HBV) and hepatitis C virus (HCV), similar to HIV/HCV and HIV/HBV coinfected individuals, are more likely to develop severe hepatic diseases (2) (3) . Mortality rate is higher among HBV/HCVcoinfected individuals (7.1%) compared to HCV and HBV monoinfected individuals with 3.2% and 5.3%, respectively (4) . Compared to patients with HBV and HCV coinfection, patients monoinfected with HCV are more responsive to IFN therapy (5) (6) . Occult HBV infection, a condition in which HBV DNA and not HBsAg is detectable, may elevate the risk of hepatic diseases as well as the rate of nonresponse to conventional treatment of HCV (7) . Due to shared routes of transmission, coinfection with HBV and HCV, particularly in endemic areas, is not uncommon (8) . Dual infection is not limited to viral hepatitis C and B and clinical conditions may also vary. Senturk et al. concluded that HBV/HDV coinfection may have more serious implications compared to dual infection with HBV and HCV (9) . Contradictory results have been reported regarding the extent to which HBV or HCV is dominant among patients with HBV and HCV coinfection; with more findings suggesting the suppression of HBV (10) (11) (12) (13) (14) . Other in vitro findings have confirmed that HCV, through its core protein, brings about suppression of HBV replication (15) (16) (17) . On the other hand, other studies showed that the dominance can change over the period of infection and some others reported the dominance of HBV (18) (19) . According to some limited studies, the treatment for HBV/HCV-coinfection is not straightforward and needs to be adjusted for individuals with different response rates (3, 5, 20) . At the present time, no specific treatment guideline exists for this group of patients (21) . A study by Liu in 2009 suggested that combination therapy with peginterferon alfa-2a and ribavirin is suitable for treating both HCV monoinfected and HBV/HCV coinfected individuals to the same extent (21) . In another study, PEG-IFN-a2b and ribavirin was found to be effective in suppression of HCV among HBV/HCV-coinfected individuals (22) . The aim of this study was to determine the prevalence rate of HCV infection among patients with HBV infection in the general population of Mashhad.
Methods
According to multi-stage cluster sampling method, from March 2010 to November 2011, 3198 people from the general population of Mashhad were screened for HBV infection and HBsAg detection was determined by ELISA, as described previously (23) . The current study was ethically approved by Mashhad University of Medical Sciences. Following obtaining of informed consent, 10 milliliters blood sample was collected from each participant. Thirty four patients positive for HBsAg were then subjected for anti-HCV antibody screening by ELISA method (Delaware Biotech, USA).
Results
In the studied group, patients who were positive for HBsAg included 17 (50%) men and 17(50%) women with the mean age of 47.1±9.7 (range 19-63 years); none of them were found to be positive for HCV antibody by ELISA. Among 34 patients with HBV/HCV co-infection, one patient (2.94%), 26 patients (76.47%), and one patient (2.94%) were positive for HBeAg, HBeAb and HBc-IgM, respectively. HD-Ag was not detected in our infected patients. ELISA results for HBeAg, HBeAb and HBc-IgM in men and women were not statistically significant (P-value=0.999) ( Table 1) . Also one patient (2.94%) was positive for HBV using PCR method.
Discussion
Up to now, no large-scale studies have pointed out the global prevalence of HBV/HCVcoinfection. In addition to this fact, since occult HBV infection cannot be detected unless by sensitive molecular biology techniques, HBsAg screening, on its own, may not detect all cases of HBV (7, (24) (25) . Unlike this study which was performed in Iran and found no case of HBV/HCV coinfection, several studies in various regions of the world reported different prevalence rates. To mention some of them, In Taiwan, a prevalence rate of 3.4%, 12% and 18% was reported in 1991, was observed in 21% of patients with injecting drug usage in Tehran, Iran (39) . In another study in Tehran which was performed among patients with Human Immunodeficiency virus, the prevalence rate of 36.3% was observed for HBV/HCV coinfection (40) . The authors' previous studies among the population of Mashhad showed the HBsAg positivity of 0.53% (23) and the prevalence rate of 0.13% for Hepatitis C virus infection (41) . In the current study, none of the patients positive for HBsAg were positive for anti-HCV. Detection of dual infection with HBV and HCV can contribute to its clinical management. Further studies with more sensitive molecular biology techniques to detect all cases of HBV are required to better understand the prevalence of HBV/HCV-co infection in the population of Mashhad, Iran.
